Genorare B.V.

Genorare B. V. , based in the Netherlands, specializes in advanced diagnostic solutions that enhance the identification and management of rare diseases through innovative technology integration. Founded by Quy Reinhard, Genorare B.

V. is headquartered in Amsterdam, Netherlands. The company is focused on developing diagnostic tools for rare diseases, without any significant pivots or changes in business operations reported. They have completed one deal as of June 1, 2025.

Genorare specializes in advanced diagnostic solutions aimed at transforming the identification and management of rare diseases. The company’s core product offerings include a platform that integrates predictive intelligence, genomic data analysis, and Fully Homomorphic Encryption (FHE) to deliver rapid and secure diagnostic insights. This innovative platform assists healthcare professionals by analyzing encrypted Electronic Health Records (EHR) and genomic data, enabling earlier detection of rare diseases while maintaining patient privacy. Genorare's services cater primarily to hospitals, research institutions, and pharmaceutical companies across various geographical markets, including Europe and North America.

Genorare generates revenue through a subscription-based model, providing clients access to its diagnostic platform and associated services. Clients, including healthcare providers and pharmaceutical companies, pay for subscriptions that offer varying levels of access to the platform's features, including real-time EHR analysis and predictive intelligence capabilities. This structure enables scalable partnerships, meeting diverse needs in rare disease diagnostics. The company's flagship products are essential in facilitating connections between patients and clinical trials, enhancing value in the rare disease therapeutic landscape.

In June 2025, Genorare B. V. raised an undisclosed amount of pre-seed funding from new investor NLC. The company plans to utilize these funds to support the development of new products and enhance their diagnostic platform.

Upcoming initiatives include the expansion into new markets, specifically targeting additional regions in Europe and North America by 2026.